Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;65(1):32-50.
doi: 10.1007/s12088-024-01273-y. Epub 2024 Apr 27.

Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics

Sree Teja Paritala #  1 , Gunjan Gandhi #  1 , Karishma Agrawal #  1 , Pinaki Sengupta  1 , Nitish Sharma  1
Affiliations

Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics

Sree Teja Paritala et al. Indian J Microbiol. 2025 Mar.

Abstract

Glycopeptides have emerged as life-saving therapeutics in treating various gram-positive bacterial infections. Vancomycin being the first therapeutically approved glycopeptide has turned out as a blockbuster drug in the mitigation of gram-positive infections. However, long-term misuse of these glycopeptides led to the development of resistance which became a bottleneck in tackling various infections. Antimicrobial resistance has become a global threat exposing their impact on the public health domain. Concomitant to this the second-generation glycopeptides were developed through structural alterations and were approved by the USFDA which are serving as a last resort for an effective treatment. However, resistance against these also might develop shortly when misused. In this aspect, strategic approaches concerning structural activity for enhancing the antimicrobial activity and overcoming resistance were conferred. The clinical use of glycopeptides were also limited due to associated toxicity concerns and unusual pharmacokinetics. Understanding the pharmacokinetics of glycopeptides in different clinical conditions are necessary in tackling drug-induced resistance due to overdosing. Hence, dose optimization and therapeutic drug monitoring in different clinical conditions is necessary for better safety profiles and toxicity reduction. So, this review provides insights into glycopeptide-induced resistances, aspects of structural modifications to overcome resistance and their implications on pharmacokinetics and pharmacodynamics in different clinical conditions.

Keywords: Antimicrobials; Glycopeptides; Pharmacokinetics and pharmacodynamics; Resistance.

PubMed Disclaimer

References

    1. Kahne D, Leimkuhler C, Lu W, Walsh C (2005) Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 105:425–448. 10.1021/cr030103a - PubMed
    1. McComas CC, Crowley BM, Boger DL (2003) Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions. J Am Chem Soc 125:9314–9315. 10.1021/ja035901x - PubMed
    1. Sarkar P, Yarlagadda V, Ghosh C, Haldar J (2017) A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. Medchemcomm. 8:516–533. 10.1039/C6MD00585C - PMC - PubMed
    1. Dhanda G, Sarkar P, Samaddar S, Haldar J (2018) Battle against vancomycin-resistant bacteria: recent developments in chemical strategies. J Med Chem 62:3184–3205. 10.1021/acs.jmedchem.8b01093 - PubMed
    1. Acharya Y, Dhanda G, Sarkar P, Haldar J (2022) Pursuit of next-generation glycopeptides: a journey with vancomycin. Chem Commun 58:1881–1897. 10.1039/D1CC06635H - PubMed